DavidPWarshalMD

Clinical Trials

• Radiation Therapy With or Without Cisplatin in Treating Patients With Recurrent Endometrial Cancer Start of enrollment: 2008 Feb 25

  Active, not recruiting

  Phase 2

• Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Start of enrollment: 2007 Dec 06

  Active, not recruiting

  Phase 3

• Elesclomol Sodium and Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Start of enrollment: 2010 Dec 13

  Completed

  Phase 2

• Cisplatin and Radiation Therapy With or Without Carboplatin and Paclitaxel in Patients With Locally Advanced Cervical Cancer Start of enrollment: 2012 Jan 09

  Completed

  Phase 3

• Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery Start of enrollment: 2012 Jun 04

  Terminated

  Phase 3

• Radiation Therapy, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Locally Advanced Squamous Cell Cancer of the Vulva Start of enrollment: 2012 Jul 02

  Active, not recruiting

  Phase 2

• Psychological Interventions for Gynecologic Cancer Start of enrollment: 2010 Jun 01

  Completed

  Not Applicable

• Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer Start of enrollment: 2014 Mar 17

  Active, not recruiting

  Phase 2, Phase 3

• Study With Afuresertib and Paclitaxel in Platinum Resistant Ovarian Start of enrollment: 2020 Jun 09

  Active, not recruiting

  Phase 2

• Levonorgestrel-Releasing Intrauterine System With or Without Everolimus in Treating Patients With Atypical Hyperplasia or Stage IA Grade 1 Endometrial Cancer Start of enrollment: 2015 Sep 23

  Active, not recruiting

  Phase 2

  Roles: Contact, Principal Investigator

• IMGN853 With Carboplatin in Second-line Treatment of FRα Expressing, Platinum-sensitive Epithelial Ovarian Cancer Start of enrollment: 2022 Sep 28

  Active, not recruiting

  Phase 2

  Roles: Principal Investigator, Contact

• Join now to see all